Journal of Gynecologic Oncology

Papers
(The TQCC of Journal of Gynecologic Oncology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer51
FIGO staging of endometrial cancer: 202350
The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer31
Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis29
PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies26
Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial26
Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer25
Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy22
Major clinical research advances in gynecologic cancer in 202021
Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study21
Major clinical research advances in gynecologic cancer in 202120
Comparison between laparoscopic and abdominal radical hysterectomy for stage IB1 and tumor size <2 cm cervical cancer with visible or invisible tumors: a multicentre retrospective study20
Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis19
Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)19
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)18
MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas17
Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome17
Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis17
Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway17
The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis16
Recurrence risk factors in stage IA grade 1 endometrial cancer16
Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol 16
LncRNA XIST promotes carboplatin resistance of ovarian cancer through activating autophagy via targeting miR-506-3p/FOXP1 axis16
Clinicopathological and molecular characterization of high-grade endometrial carcinoma with POLE mutation: a single center study15
The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer15
Association of menopause, aging and treatment procedures with positive margins after therapeutic cervical conization for CIN 3: a retrospective study of 8,856 patients by the Japan Society of Obstetri15
Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment15
Financial toxicity in patients with gynecologic malignancies: a cross sectional study15
Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset14
The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer13
Total laparoscopic vs. conventional open abdominal nerve-sparing radical hysterectomy: clinical, surgical, oncological and functional outcomes in 301 patients with cervical cancer13
Sentinel node mapping in endometrial cancer13
Minimally invasive radical hysterectomy and the importance of avoiding cancer cell spillage for early-stage cervical cancer: a narrative review13
SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis12
Lymphadenectomy issues in endometrial cancer12
Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma12
Paraaortic sentinel lymph node detection in intermediate and high-risk endometrial cancer by transvaginal ultrasound-guided myometrial injection of radiotracer (TUMIR)11
A prospective comparison of the diagnostic accuracies of ultrasound and magnetic resonance imaging in preoperative staging of endometrial cancer11
Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-311
Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)11
Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic11
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Onco11
Fertility-sparing surgery for women with stage I cervical cancer of 4 cm or larger: a systematic review10
Total mesometrial resection (TMMR) for cervical cancer FIGO IB–IIA: first results from the multicentric TMMR register study10
Cancer field surgery in endometrial cancer: peritoneal mesometrial resection and targeted compartmental lymphadenectomy for locoregional control10
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer10
Treatment and outcomes in undifferentiated and dedifferentiated endometrial carcinoma10
TP53 variants in p53 signatures and the clonality of STICs in RRSO samples10
Preclinical investigation of patient-derived cervical cancer organoids for precision medicine9
Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience9
Trends in cervical cancer screening rates among Korean women: results of the Korean National Cancer Screening Survey, 2005–20209
The prognostic significance of tumor-infiltrating lymphocytes in cervical cancer9
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer9
Cause-specific mortality rate of ovarian cancer in the presence of competing risks of death: a nationwide population-based cohort study9
Circular RNA intraflagellar transport 80 facilitates endometrial cancer progression through modulating miR-545-3p/FAM98A signaling9
Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer9
Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study9
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial9
Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women9
Real-time intraoperative ureter visualization with a novel Near-Infrared Ray Catheter during laparoscopic hysterectomy for gynecological cancer8
Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer8
Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy8
Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer8
Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group8
The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines e8
Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer8
Mapping the robotic hysterectomy learning curve and re-establishing surgical training metrics8
Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients8
Rectosigmoid resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer: morbidity of gynecologic oncology vs. colorectal team8
Incidence and treatment outcomes of uterine cervical cancer in Korea 1999–2018 from the national cancer registry8
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer7
Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study7
Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment7
Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis7
Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary per7
Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes7
PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia7
Levonorgestrel-releasing intrauterine system-based therapies for early-stage endometrial cancer: a systematic review and meta-analysis7
Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction7
Effect of Pap smear screening on cervical cancer stage at diagnosis: results from the Korean National Cancer Screening Program7
Why was GOG-0213 a negative trial?7
Protective ostomies in ovarian cancer surgery: a systematic review and meta-analysis7
Current status and future directions of ovarian cancer prognostic models7
Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer7
A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer7
Impact of incomplete surgery and adjuvant chemotherapy for the intraoperative rupture of capsulated stage I epithelial ovarian cancer: a multi-institutional study with an in-depth subgroup analysis6
A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study6
Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer6
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients withBRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemother6
Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 20206
Immunonutrition in ovarian cancer: clinical and immunological impact?6
Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix6
Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer6
Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic6
Molecular classification of endometrial cancer: entering an era of precision medicine6
An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva6
0.050816059112549